Trial-results highlights
Clinical trials have been conducted to investigate Relatlimab for patients with melanoma. One key study, NCT03470922, known as RELATIVITY-047, explored the outcome of Progression Free Survival (PFS). PFS measures the length of time patients live without their disease getting worse or without dying, from the point of randomization, and was followed for up to approximately 33 months in this study. In RELATIVITY-047, patients were assigned to different treatment groups. The median PFS for patients who received the combination of Relatlimab and Nivolumab (Arm A) was reported as 10.12 Months. For patients in the Nivolumab-alone arm (Arm B), the median PFS was 4.63 Months.
Another study, NCT05002569, referred to as RELATIVITY-098, also investigated outcomes for melanoma, specifically focusing on Recurrence Free Survival (RFS). RFS measures the length of time after treatment that a patient remains free of the disease or its return, and this endpoint was evaluated over approximately 27.5 months. In RELATIVITY-098, among the different treatment approaches studied, the median RFS for Treatment 2 was observed to be 33.84 Months.
All values presented here are sourced from primary registry reporting. For clinical decisions, individual published papers should be consulted.